U.S. Pharmaceutical Contract Development And Manufacturing Organization Market (2026 - 2033) Size, Share & Trends Analysis Report By Type (Small Molecule, Large Molecule), By Product, By Services, By Workflow (Clinical, Commercial), By Therapeutic Area, By End-use, And Segment Forecasts

U.S. Pharmaceutical CDMO Market Summary

The U.S. pharmaceutical CDMO market size was valued at USD 38.8 billion in 2025 and is projected to grow from USD 41.2 billion 2026 to USD 65.3 billion by 2033, at a CAGR of 6.8% from 2026 to 2033. The U.S. pharmaceutical CDMO is advancing, driven by the growth of biologics, biosimilars, and advanced therapies, rising demand for outsourcing in drug development, and increasing clinical trial activity and pipeline expansion. The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced therapies such as cell and gene therapies, fueling demand for specialized CDMO services.

Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house. The U.S. market is witnessing significant growth in biologics, biosimilars, and advanced cell and gene therapies, fueling demand for specialized CDMO services. Developing and manufacturing these therapies requires advanced capabilities like single-use bioprocessing systems, viral vector production, and personalized medicine expertise, which many pharma companies lack in-house. CDMOs provide infrastructure, regulatory knowledge, and innovation platforms to accelerate development while meeting FDA standards. With rising approvals of biologics and biosimilars in the U.S., CDMOs are becoming indispensable partners in scaling production, ensuring supply chain resilience, and enabling faster time-to-market for complex, high-value therapeutics.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

In addition, to cut expenses, shorten turnaround times, and concentrate on core skills like research and development and marketing, pharmaceutical corporations in the U.S. are increasingly contracting with CDMOs to handle drug development and manufacture. Small and mid-sized biotech companies, which make up the majority of the U.S. innovation scene, can obtain specialized knowledge, innovative technologies, and regulatory support through outsourcing without making significant infrastructure investments. CDMOs are essential partners in the changing pharmaceutical value chain because they provide flexible capacity, scalability, and compliance with strict FDA standards. As biologics, cell and gene therapies, and specialty medication formulations become more sophisticated, this trend is expected to speed up. U.S. leads globally in clinical research, with thousands of active clinical trials supported by a robust biotech and pharmaceutical ecosystem.

The growing number of innovative drugs in the pipeline, particularly in oncology, rare diseases, and immunotherapies, drives demand for CDMO services across preclinical, clinical, and commercial stages. CDMOs provide essential expertise in formulation development, manufacturing clinical trial material, analytical testing, and regulatory submissions. As small biotech firms dominate innovation but lack in-house production facilities, they increasingly rely on CDMOs to accelerate time-to-market, reduce risks, and ensure compliance with evolving FDA guidelines, reinforcing their critical role in the pharmaceutical landscape.

Market Dynamics

Impact of U.S. Tariffs on the U.S. Pharmaceutical CDMO Market

The imposition of U.S. tariffs on raw materials, intermediates, laboratory tools, and APIs has led to an increase in operating costs among pharmaceutical contract development and manufacturing organizations in the U.S. Numerous pharmaceutical sponsors who source chemical intermediates and excipients from China and other Asian countries have experienced procurement price changes that are impacting their generics and small molecules manufacturing capabilities. The pricing issue associated with tariffs has driven pharmaceutical sponsors to diversify their supplier base by outsourcing manufacturing processes to their own countries. In addition, pharmaceutical sponsors are looking at CDMOs based in the U.S. with advanced manufacturing capabilities for API and finished dosage formulations. Furthermore, increased import taxes on advanced manufacturing equipment and bioprocessing materials have raised the capital costs of expanding manufacturing facilities, especially those involved in biologics and sterile drugs. In addition, the current tariff environment is driving more strategic partnerships, regional investments in manufacturing capacity, and long-term purchase agreements in the U.S. pharmaceutical CDMO industry.

Technological Advancements

To learn more about this report, Download Free Sample Report

The U.S. pharmaceutical CDMO market is undergoing a drastic shift towards continuous manufacturing to increase production efficiency, reduce waste, and accelerate the commercial production of advanced therapeutic drugs. Innovative biopharmaceutical technologies are gaining momentum due to the increasing number of monoclonal antibodies, recombinant proteins, and novel biopharmaceuticals being developed. Digitalization and the implementation of Industry 4.0 technologies are changing the manufacturing processes with real-time tracking, predictive maintenance, automation of quality control, and process optimization based on data analysis. The growing interest in the production of high-potency APIs is driving demand for containment manufacturing facilities for oncology and targeted treatments. The cell and gene therapy platform is proving to be a major growth factor for the industry, fueled by investments in viral vector production, personalized medicines, and regenerative medicines.

There is an increase in the adoption of modular manufacturing capabilities that accommodate batch-size flexibility and enable rapid scale-up for innovative biotech companies. In addition, there is a growing trend among pharmaceutical sponsors to opt for service providers that offer integrated analytical testing, formulation development, and sterile fill-finish capabilities to speed up the drug development process. Advances in automation technologies are ensuring better operational consistency and reducing manual intervention during critical manufacturing processes, especially in biologics manufacturing plants. Advanced manufacturing capabilities for complex drug modalities have become critical with the focus on precision medicine in the pharmaceutical pipeline.

Pricing Model Analysis

To learn more about this report, Download Free Sample Report

There is an increasing trend towards diversification in the pricing strategies of U.S. pharmaceutical CDMOs, as companies leverage flexible business models based on project complexity, sponsor involvement, and the need for long-term partnerships. Milestone-based pricing is popular in drug development projects, in which fees are set for regulatory filing, clinical trial readiness, and manufacturing scale-up milestones. This is done to allow the sponsor to control the financial risk associated with drug development phases. Value-based pricing has become prevalent in complex biologics and advanced therapies projects where fees are tied to specific performance metrics like accelerated product commercialization and improved process efficiency. Fixed fees are typical of well-defined projects such as formulation development, analytical services, and batch manufacturing.

The subscription model is becoming increasingly popular among new biotech companies that need consistent access to manufacturing facilities, regulatory support, and expertise in product development. The complexity of pharmaceutical pipelines is causing pharmaceutical companies to adopt hybrid pricing models that combine operational costs with performance-based incentives to enhance their commercial flexibility. Moreover, contract development and manufacturing organizations that can offer integrated services and specialize in manufacturing are witnessing premium pricing opportunities due to high demand for their services.

Market Concentration & Characteristics

The U.S. pharmaceutical CDMO market growth stage is moderate, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.

The U.S. pharmaceutical CDMO market is structured by continuous innovation in biologics, cell and gene therapies, and advanced drug delivery systems. Adoption of AI, automation, and continuous manufacturing boosts efficiency and quality. For instance, in April 2025, Regeneron expands U.S. biologics manufacturing with FUJIFILM Diosynth, investing over USD 3 billion to double capacity and drive innovation.

Mergers and acquisitions remain high in the U.S. pharmaceutical CDMO market, driven by the need to expand biologics capacity, advanced technologies, and geographic reach. For instance, in August 2025, ESTEVE acquired Regis Technologies, expanding U.S. CDMO presence and strengthening small-molecule API development and manufacturing capabilities across global facilities. Strategic deals allow CDMOs to integrate end-to-end services, strengthen supply chain resilience, and broaden expertise

To learn more about this report, Download Free Sample Report

The U.S.'s changing regulatory landscape and stringent FDA regulations have a big impact on CDMO operations. Although compliance guarantees product efficacy, safety, and market acceptance, it also lengthens turnaround times and increases operating expenses. While smaller businesses could find it difficult to meet strict criteria, CDMOs with strong regulatory knowledge gain a competitive edge by helping sponsors navigate complicated approval processes.

Service expansion in the U.S. pharmaceutical CDMO market is driven by demand for integrated offerings covering preclinical development, clinical trials, commercial-scale production, and packaging. CDMOs are increasingly offering customized formulations, high-potency APIs, and biologics production. In long-term pharmaceutical pipelines, increasing capabilities guarantees client retention, lessens outsourced fragmentation, and establishes CDMOs as strategic partners as opposed to transactional vendors.

End-user concentration affects U.S. CDMOs because large pharmaceutical companies dominate contract quantities while biotech startups generate demand driven by innovation. A strong reliance on a small number of large clients ensures consistent, high-value projects, despite raising revenue risks. Since diversifying clients among small biotechs and mid-sized pharmaceutical businesses enhances stability, CDMO success depends on flexibility, scalability, and tailored services.

Type Insights

On the basis of type, the small molecules segment accounted for the largest revenue share in 2025, at 72.9%, and is also the fastest-growing segment over the forecast period. The market is driven by high demand for generic drugs, oral solid dosages, and active pharmaceutical ingredients (APIs). Pharmaceutical businesses are drawn to contract development and manufacturing services for small molecules because they provide streamlined production, cost-effective solutions, and assistance with regulatory compliance. The segment benefits from extensive outsourcing trends, patent expirations, and rising R&D in specialty and generic small-molecule drugs. This segment is further strengthened by CDMOs' proficiency with complicated and high-potency formulations, which firmly establishes its dominance in revenue creation within the pharmaceutical contract development and manufacturing industry in the U.S.

The large molecules segment is expected to witness the second fastest growth rate over the forecast period, driven by increasing demand for biologics, monoclonal antibodies, and complex protein-based therapies. Rising prevalence of chronic diseases, cancer, and autoimmune disorders fuels the need for innovative biologic treatments, prompting pharmaceutical companies to outsource development and manufacturing to specialized CDMOs. Advanced capabilities in cell culture, purification, and formulation enable efficient production of high-value biologics while ensuring regulatory compliance and quality standards. Expanding investment in biopharmaceutical infrastructure, technological advancements, and expertise in handling large molecules further accelerates growth, positioning this segment as a key driver in the U.S. pharmaceutical CDMO market.

Product Insights

On the basis of product, the active pharmaceutical ingredients (APIs) accounted for the largest revenue in 2025, driven by the growing demand for biologics and complicated compounds. In an effort to cut expenses, boost productivity, and guarantee regulatory compliance, pharmaceutical companies are increasingly contracting with CDMOs to design and produce APIs. The need for premium APIs is developing quickly because of the rising incidence of uncommon and chronic diseases. Advanced capabilities, including continuous processing, green chemical solutions, and high-potency API production, are offered by CDMOs. Outsourcing is also fueled by the FDA's strict requirements, which demand infrastructure and knowledge. Because of this high demand, APIs are the leading source of income in the U.S. pharmaceutical CDMO market.

The drug product segment is projected to grow at the second-fastest growth rate duringthe forecast period. The segment is driven by the need for sterile injectables, biologics, and sophisticated formulations. Pharmaceutical firms are increasingly contracting out the creation of new drugs in order to save costs, gain access to specialist knowledge, and maintain regulatory compliance. For instance, a strategic acquisition made by Simtra BioPharma Solutions in July 2025 to increase the U.S.' capacity for injectable medications, such as antibody-drug conjugates (ADCs). Simtra demonstrates the growing potential of the industry by establishing itself as the first CDMO in the U.S. to provide commercial-scale ADC medicinal product manufacturing. The need for outsourced drug product services is increasing because of rising innovation, the expansion of oncology pipelines, and domestic supply chain requirements.

Service Insights

On the basis of service, the contract manufacturing segment held the largest revenue segment in 2025, supported by strong demand for large-scale biologics and advanced drug production. Companies increasingly outsource to CDMOs to access specialized facilities, expertise, and cost-efficient scalability. In June 2025, developments, such as UCB's USD 5 billion investment in a U.S. biologics facility and its expansion of partnerships with CMOs, highlight the vital role contract manufacturing plays in supporting growth drivers and future pipelines. By enabling pharmaceutical firms to focus on innovation while ensuring reliable, high-quality output, contract manufacturing continues to be the backbone of the U.S. pharmaceutical CDMO market's revenue leadership.

The contract development segment is projected to grow at a significant CAGR duringthe forecast period. The segment is driven by rising demand for advanced R&D, drug formulation, and specialized development capabilities. Pharmaceutical firms increasingly seek CDMO partnerships to accelerate pipelines and address complex therapies. A strong development is Hikma Pharmaceuticals USA's USD 1 billion investment by 2030 to expand U.S. manufacturing and development capacity. With over USD 4 billion invested in the past 15 years and proven FDA collaboration, Hikma demonstrates how contract development drives innovation, supports affordable access to medicines, and positions CDMOs as critical partners in shaping the U.S. pharmaceutical landscape.

Workflow Insights

On the basis of workflow, the commercial segment was the largest revenue contributor in the U.S. pharmaceutical CDMO market in 2025, fueled by the rising demand for large-scale manufacturing of biologics, generics, and specialty medicines. As pharmaceutical pipelines mature, CDMOs provide the expertise, compliance, and capacity needed to transition from clinical to full-scale production. This includes advanced biologics, oncology therapies, and complex injectables. The commercial stage generates consistent revenue streams through long-term supply agreements and scalability advantages. Additionally, increasing FDA approvals and expanding biologics portfolios create opportunities for CDMOs to support lifecycle management and global supply continuity, making commercial manufacturing the dominant and most stable revenue segment.

The clinical segment is projected to grow at the fastest CAGR duringthe forecast period. The segment growth is driven by rising demand for specialized manufacturing to support advanced therapies and complex trial requirements. Partnerships such as in September 2025, Hemogenyx Pharmaceuticals' collaboration with Made Scientific for CAR-T therapy HG-CT-1 highlight the growing reliance on CDMOs with expertise in cell and gene therapies, biologics, and oncology drugs. These partnerships accelerate Phase I and II trials, ensure regulatory compliance, and enable flexible manufacturing for smaller batch sizes. Increasing clinical trial activity, particularly in rare diseases and immunotherapies, combined with robust FDA approvals, positions the clinical segment as the most dynamic growth driver.

Therapeutic Area Insights

On the basis of therapeutic area, the oncology segment accounted for the largest revenue in 2025 and is the fastest-growing segment, driven by the growing global cancer burden. Rising demand for innovative oncology therapies-including targeted treatments, immunotherapies, and personalized medicines-fuels CDMO engagement. Increasing R&D investments, patent expirations, and the need for biologic innovations further boost growth. For instance, in January 2024, Theragent Inc secured U.S. FDA clearance of CellVax Therapeutics' IND for FK-PC101, a personalized prostate cancer immunotherapy, with Phase II patient recruitment starting in March 2024.

The autoimmune diseases segment is anticipated to grow at the second-fastest growth rate over the analysis period. The growing incidence of autoimmune diseases and the need for novel treatments are driving the advancement of the autoimmune diseases segment in the U.S. pharmaceutical CDMO market. CDMOs are increasingly focusing on developing best-in-class products and supporting rare autoimmune disease treatments. Such factors play a critical role in speeding up CDMO-driven drug development and commercialization for autoimmune disease therapies.

End-use Insights

On the basis of end use, the large pharmaceutical companies accounted for the largest revenue segment in the U.S. pharmaceutical CDMO market in 2025, due to their widespread outsourcing of drug development and manufacture to satisfy rising demand. These businesses use CDMOs for cost effectiveness, scalability, and specialist knowledge, especially in the fields of difficult small-molecule medicines, oncology, and biologics. Long-term agreements and strategic alliances guarantee CDMOs consistent revenue streams. Large pharmaceutical companies also make investments in customized medicine and novel therapeutics, necessitating the enhanced manufacturing capabilities that CDMOs offer. The partnership enables faster time-to-market, regulatory compliance, and risk mitigation, firmly establishing this market segment as the main driver of revenue growth for the U.S. pharmaceutical CDMO market.

To learn more about this report, Download Free Sample Report

The small pharmaceutical companies segment is anticipated to witness the fastest growth in the U.S. pharmaceutical CDMO market, owing to the growing number of emerging biotechnology and virtual pharmaceutical firms with inadequate manufacturing capabilities. Small pharmaceutical companies rely heavily on CDMOs for services such as drug development, testing, clinical trials, regulatory assistance, and commercial manufacturing, which help in faster commercialization timelines. The increased interest among small pharmaceutical firms in developing biologics, orphan drugs, personalized medicines, and specialty therapeutics is driving the need for more outsourcing services in the country. In addition, increased venture capital investments and investigational new drug applications from small pharmaceutical firms are driving higher outsourcing expenditures in the U.S.

Key U.S. Pharmaceutical CDMO Company Insights

The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in June 2025, Agenus Inc. partners with Zydus Lifesciences, exchanging its U.S. biologics CMC facilities for USD 75M plus contingent payments. The collaboration establishes Zydus’ BioCDMO operations, with Agenus as its first customer, supporting global manufacturing, clinical development, and commercialization of botensilimab and balstilimab (BOT/BAL), unlocking asset value and regulatory readiness.

Key U.S. Pharmaceutical CDMO Companies

• Thermo Fisher Scientific, Inc

• Lonza

• Recipharm AB

• Catalent, Inc

• WuXi AppTec, Inc

• Samsung Biologics

• Piramal Pharma Solutions

• Siegfried Holding AG

• Corden Pharma International

• Cambrex Corporation

• Vetter Pharma

• Delpharm

• Jubilant Pharmova / HollisterStier

• Eurofins CDMO

• Almac Pharma Services

Recent Developments

• In September 2025, Hemogenyx Pharmaceuticals partners with Made Scientific CDMO to advance HG-CT-1 CAR-T therapy for relapsed/refractory AML, leveraging GMP facilities in New Jersey to accelerate Phase I clinical trials and pediatric cohorts.

• In June 2025, Hikma Pharmaceuticals USA announces USD 1 billion investment by 2030 to expand U.S. manufacturing and R&D, enhancing domestic capabilities, producing over 12 billion doses annually, and supporting affordable access to essential medicines.

• In June 2025, UCB plans major U.S. investment in a biologics manufacturing facility, generating USD 5 billion economic impact, expanding workforce, and strengthening CMO partnerships to support pipeline growth, innovation, and sustainable healthcare delivery.

U.S. Pharmaceutical CDMO Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Pharmaceutical Contract Development and Manufacturing Organization market report based on type, product, service, workflow, therapeutic area, and end-use.

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Small Molecule

    • Branded

    • Generic

  • Large Molecule

    • Biologics

    • Biosimilar

• Product Outlook (Revenue, USD Million, 2021 - 2033)

  • API

    • Traditional Active Pharmaceutical Ingredient (Traditional API)

    • Highly Potent Active Pharmaceutical Ingredient (HP-API)

    • Biologics

    • Others

  • Drug Product

    • Oral solid dose

    • Semi-solid dose

    • Liquid dose

    • Others

• Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Contract Development  

    • Pre-formulation & Formulation Development Services

    • Process Development & Optimization

    • Analytical Testing & Method Validation

    • Scale-up & Tech Transfer

  • Contract Manufacturing  

    • API Manufacturing

    • Finished Drug Products Manufacturing

  • Packaging and Labelling  

  • Regulatory Affairs  

  • Others

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)

  • Clinical

  • Commercial

• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Infectious Diseases

  • Neurological Disorders

  • Cardiovascular Disease

  • Metabolic Disorders

  • Autoimmune Diseases

  • Respiratory Diseases

  • Ophthalmology

  • Gastrointestinal Disorders

  • Orthopedic Diseases

  • Dental Diseases

  • Others

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Small Pharmaceutical Companies

  • Medium Pharmaceutical Companies

  • Large Pharmaceutical Companies

Delivered Customizations

This report has been delivered with the following In-depth customizations